Oak Harvest Investment Services Grows Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Oak Harvest Investment Services increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.6% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 2,779 shares of the biopharmaceutical company’s stock after purchasing an additional 567 shares during the period. Oak Harvest Investment Services’ holdings in Regeneron Pharmaceuticals were worth $2,921,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in REGN. Stephens Consulting LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth $26,000. Sachetta LLC increased its stake in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the period. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $28,000. Lynx Investment Advisory acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $33,000. Finally, Family Firm Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the subject of several analyst reports. Piper Sandler boosted their target price on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research note on Friday, August 23rd. Evercore ISI cut their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Barclays decreased their price target on shares of Regeneron Pharmaceuticals from $1,220.00 to $1,080.00 and set an “overweight” rating for the company in a research note on Wednesday, October 23rd. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,137.00 and set a “buy” rating for the company in a research report on Wednesday, October 16th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,101.00.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, VP Jason Pitofsky sold 487 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.5 %

Shares of Regeneron Pharmaceuticals stock opened at $922.79 on Thursday. The company’s fifty day moving average is $1,072.53 and its two-hundred day moving average is $1,040.65. Regeneron Pharmaceuticals, Inc. has a 1 year low of $772.84 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The company has a market capitalization of $101.73 billion, a P/E ratio of 24.44, a PEG ratio of 3.20 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the prior year, the business earned $8.79 EPS. The firm’s revenue was up 12.3% compared to the same quarter last year. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.6 earnings per share for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.